+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ischemia Reperfusion Injury - Pipeline Review, H1 2020

  • ID: 4911665
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 177 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Acelerox LLC
  • Argenx SE
  • Celdara Medical LLC
  • EVAS Therapeutics LLC
  • Ischemix Inc
  • NuNerve Pty Ltd
  • MORE
Ischemia Reperfusion Injury - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H1 2020, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 36 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 16 and 1 molecules, respectively.

Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Acelerox LLC
  • Argenx SE
  • Celdara Medical LLC
  • EVAS Therapeutics LLC
  • Ischemix Inc
  • NuNerve Pty Ltd
  • MORE
  • Introduction
  • Ischemia Reperfusion Injury - Overview
  • Ischemia Reperfusion Injury - Therapeutics Development
  • Ischemia Reperfusion Injury - Therapeutics Assessment
  • Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development
  • Ischemia Reperfusion Injury - Drug Profiles
  • Ischemia Reperfusion Injury - Dormant Projects
  • Ischemia Reperfusion Injury - Discontinued Products
  • Ischemia Reperfusion Injury - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Ischemia Reperfusion Injury, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Ischemia Reperfusion Injury - Pipeline by Acelerox LLC, H1 2020
  • Ischemia Reperfusion Injury - Pipeline by Affinicon ApS, H1 2020
  • Ischemia Reperfusion Injury - Pipeline by Akashi Therapeutics Inc, H1 2020
  • Ischemia Reperfusion Injury - Dormant Projects, H1 2020
  • Ischemia Reperfusion Injury - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Ischemia Reperfusion Injury, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Acelerox LLC
  • Affinicon ApS
  • Akashi Therapeutics Inc
  • Amyndas Pharmaceuticals LLC
  • Apollo Therapeutics LLC
  • Aptorum Group Ltd
  • Argenx SE
  • Armaron Bio Pty Ltd
  • Axolo Pharma Inc
  • Balmes Transplantation SAS
  • Bolder Biotechnology Inc
  • Catalyst Biosciences Inc
  • Celdara Medical LLC
  • Cellmid Ltd
  • CFM Pharma Holding BV
  • Corline Biomedical AB
  • Cypralis Ltd
  • EVAS Therapeutics LLC
  • Everon Biosciences Inc
  • Gero Discovery
  • Gilead Sciences Inc
  • Glucox Biotech AB
  • Ischemix Inc
  • Lee's Pharmaceutical Holdings Ltd
  • LG Chem Ltd
  • Limulus Therapeutics Pty Ltd
  • Mallinckrodt Plc
  • New B Innovation Ltd
  • New Horizons Pharma Inc
  • Nour Heart Therapeutics LLC
  • NuNerve Pty Ltd
  • Orion Corp
  • Pfizer Inc
  • Proteo Inc
  • Radikal Therapeutics Inc
  • Reata Pharmaceuticals Inc
  • Revive Therapeutics Ltd
  • SBI Pharmaceuticals Co Ltd
  • Stealth BioTherapeutics Corp
  • TheraSource LLC
  • United Therapeutics Corp
  • Young Therapeutics LLC
Note: Product cover images may vary from those shown
Adroll
adroll